Advancements in Understanding and Managing Activated PI3 Kinase Delta Syndrome: A Comprehensive Review

Elias A. Alraqibah

Department of Medicine, College of Medicine,Qassim University, Qassim, Saudi Arabia
Email: *e.alraqibah@qu.edu.sa,****ORCID ID:*** *0009-0007-9504-7117*

KEYWORDS

ABSTRACT

Activated PI3 kinase Delta Syndrome (APDS) is defined as a primary immunodeficiency that occurs in patients with genetic mutations in the PIK3CD or PIK3R1 genes and causes dysregulation in the immune system. The current review aims to understand this condition's pathophysiology, symptoms, and diagnosis, as well as the different therapeutic strategies. Recent developments have shed new light on the essential part of PI3Kδ in immune system control, therefore paving the way for targeted treatments such as PI3Kδ inhibitors (leniolisib and duvelisib) that have proven effective in management of lymphoproliferation, autoimmunity, and repeated infections. Highlighting the importance of early diagnosis through genetic testing and personalized medicine to optimize therapy, thereby improving patient quality of life and outcomes.

Notwithstanding these developments, there will still be important steps to take concerning the long-term treatment of APDS, particularly including the safety and longevity of present therapies and examination of other genetic mutations and possible curative options such as gene editing. The management of patients with APDS requires different combined strategies, including the efforts of geneticists, immunologists, and other experts who deal with both the psychiatric and the clinical symptoms of the disorder. Research developments promise future improvements in APDS treatment and possible cures, thanks to gene editing technologies, personalized medicine, and emerging therapeutic targets.

1. Introduction

The phosphoinositide 3-kinase (PI3K) pathway is considered one of the important signaling cascades in regulating a wide array of cellular processes that include the growth of the cells, their proliferation, survival, metabolism, and immune function [1,2]. PI3K has different isoforms, and the delta isoform (PI3Kδ) is an essential component that significantly regulates the immune system and is mainly expressed in the hematopoietic cells [3,4]. PI3Kδ is important in activating and developing different immune components, including T and B cells, and has a significant role in response to antigen-receptor signaling [5]. This pathway also influences cytokine production and cellular trafficking within lymphoid tissues [5]. Dysregulation or dysfunction of this pathway can be associated with the incidence of different immune-related disorders, such as hyperactivation of immune responses, primary immunodeficiency syndrome, or autoimmunity [6,7]. In this context, gain-of-function mutations in the PI3Kδ subunit have been implicated in a rare but significant immunological disorder known as Activated PI3 Kinase Delta Syndrome (APDS) [8,9]. Understanding this pathway is crucial for grasping the various mechanisms related to the occurrence of APDS, and it plays a significant role in exploring and developing targeted therapeutic interventions.

Activated PI3 Kinase Delta Syndrome (APDS), first described in 2013, marks a significant advancement in the study of primary immune deficiencies. This condition occurs because of gain-of-function mutations in the PIK3CD or PIK3R1 genes, and both respectively encode for catalytic (p110δ) and regulatory (p85α) subunits of the delta isoform, which results in

dysfunction of the immune system, causing the condition [10,12]. Hyperactivation of the PI3Kδ pathway follows from these mutations, leading to a series of pathological consequences, including lymphoproliferation, repeated infections, and immune dysregulation [12]. Based on the genetic mutation involved, APDS is at present divided into two primary subtypes: mutations in PIK3CD cause APDS1, and mutations in PIK3R1 result in APDS2 [13]. Though the two subtypes exhibit many similar symptoms, precise genetic testing is needed to verify the diagnosis since subtle variations in presentation and genetic mechanisms have been noticed [8]. Emphasizing the need for genetic and molecular definition in grasping immune system concerns, APDS has become a vital field of study since its discovery.

Significant advances in diagnosing and managing APDS have been reported in the last few years. Earlier and more precise diagnoses result from advances in genomic technologies that have helped to identify genetic mutations correlated with the syndrome [8]. In addition, the treatment of patients with APDS has now shifted to use target treatment as PI3Kδ inhibitors that aim to improve outcomes and increase the expected quality of life of the affected patients [13]. However, there are many remaining barriers against complete management of these conditions, including delays in diagnosis of the disorders, variation of the symptoms between patients, and possible long-term side effects of the proposed treatment. It is, therefore, vital to always keep current knowledge of APDS to connect these divides and improve patient care [14]. The current review aims to understand the genetics, the mechanisms of the disease, the clinical characteristics of the condition, the diagnosis, and the development of possible treatment, depending on the summary of the most recent studies considering APDS. This overview attempts to emphasize the development achieved and map out the next steps for study and clinical practice in this speedily changing field by compiling the latest research.

2. Genetics and Molecular Pathophysiology

Mutations in *PIK3CD* and *PIK3R1* Genes

Mutations in the PIK3CD and PIK3R1 genes lead to a gain of function in PI3 Kinase Delta Syndrome (APDS), a monogenic condition, as they encode crucial elements of the PI3Kδ pathway. PIK3CD gene encodes the catalytic subunit of PI3Kδ, p110δ; PIK3R1 encodes the regulatory subunit, p85α [6]. Mutations in these genes lead to PI3Kδ signaling pathway hyperactivity, which interferes with regular immune activity [15]. Mutations in PIK3CD, found in APDS1, usually cause amino acid substitutions that increase p110δ's enzyme activity, for example, the E1021K mutation. [16]. On the other hand, mutation of PIK3R is related to the incidence of APDS2, which prevents the interaction between p85α and p110δ, causing uncontrolled management of the enzyme subunits [17,18]. Both subtypes are considered inherited in the autosomal dominant pattern. The literature reports both familial and sporadic cases associated with de novo mutations. Additionally, paternal and maternal gonadal mosaicism has been suggested in relation to APDS1, which helps clarify the confusing inheritance pattern of this disease [19,20]. Most importantly, these genetic results highlight the need for genetic testing for precise diagnosis and classification of APDS, which is vital for directing personalized treatments.

Impact on Immune System Regulation

Proper immune response control depends much upon the PI3Kδ pathway [5]. B cells and T cells activation, proliferation, and regulatory T cell differentiation (Tregs) [21,22] depend critically on it. Especially vital for antigen receptor-mediated lymphocyte activation is PI3Kδ signaling; it helps immune cell survival and generates vital cytokines [3]. Sustained hyperactivation of this pathway follows gain-of-function mutations in PIK3CD and PIK3R1, causing several different immune dysregulation [23]. Overactivity in PI3Kδ signaling, for example, allows for lymphocyte growth and survival, thereby causing lymphadenopathy and splenomegaly, characteristic signs of APDS [23]. In addition, this disorder is associated with

frequent incidences of infections and weakened immune system defense because of the dysregulation of the signaling that inhibits the formation of T-cell memory and the production of B-cell antibodies. The complexity of the condition and the need for specific treatments that can help balance the immune system is underscored by this paradox of hyperactivity, resulting in immune system exhaustion.

Mechanisms Leading to Immunodeficiency and Dysregulation

The PI3Kδ pathway hyperactivating in APDS has great consequences for immune system equilibrium. One big effect is the disturbance of regular lymphocyte growth and activity [24]. B cells display compromised class-switch recombination, so lower levels of immunoglobulin subclasses and scanty vaccine and infection antibodies reaction [25,26]. T cells also show decreased activity, including a reduced ability to mount efficient reactions to pathogenic insults. Furthermore, chronic PI3Kδ pathway activation helps with immune dysregulation, which reveals itself as inflammatory symptoms and autoimmunity. APDS patients, for instance, frequently develop autoimmune cytopenias, symptoms similar to those of inflammatory bowel disease, and other symptoms of immune hyperactivation [27]. These events have a molecular basis, including direct effects of PI3Kδ hyperactivity but also secondary changes in downstream signaling molecules such as the mTOR pathway and transcription factors controlling immune regulation [15]. Together, these processes account for the complex clinical presentation of APDS, which includes both immunodeficiency and immune regulation features.

Splice donor site mutations, such as c.1425+1G> (A, C, T) (p.434–475del), lead to exon 11 skipping in the p85α subunit, disrupting its regulatory function. The p110δ subunit catalyzes the conversion of phosphatidylinositol-4,5-bisphosphate to phosphatidylinositol-3,4,5-trisphosphate, which anchors signaling proteins like PDK1 and AKT. Mutations in p110δ result in hyperactivation of the AKT/pS6K/mTOR pathway, classifying them as gain-of-function mutations, while mutations in p85α remove its inhibitory control over p110, increasing PI3K activity. Since the mTOR pathway regulates essential cellular processes such as growth, metabolism, and immune function, its dysregulation leads to significant immune system alterations in affected individuals [28,29].

3. Epidemiology and Demographics

Global Prevalence of APDS

Activated PI3 Kinase Delta Syndrome (APDS) is a rare primary immunodeficiency disorder, with its exact prevalence still not fully established [13]. The prevalence of APDS across studies showed its scarcity worldwide [10,11,13], ranging from studies that did not report a prevalence to others that reported just 1-2 cases per million individuals [10,13]. Several studies found, however, that there is a perception this frequency is seen underdiagnosis owing to its clinical overlap with symptoms of several other immunodeficiencies and other immune dysregulation syndromes [11–13]. Developments in genetic testing and the rise of whole-exome sequencing have helped to find more cases in recent years, indicating that APDS's actual frequency might be higher than currently published [13]. Notwithstanding its infrequency, it is acknowledged as a major cause of morbidity associated with immune dysregulation in the affected individuals, pointing to the need for genetic counseling and clinical management [27]. In regions where access to genetic testing is limited, ongoing research is expected to shed light on the global impact of APDS.

Regional and Cohort-Specific Variations

The rate of APDS cases has been reported in different regions, indicating some regional variations that describe and identify its existence [12]. Studies have shed light on instances from Europe, North America, the Middle East, and Asia, with different clinical presentations depending on the population investigated. Cohorts from Western countries, for instance,

usually have earlier access to diagnostic equipment and, therefore, more regular identification of the disease [13]. In regions with constrained health resources, underdiagnosis was more common because of the unavailability of diagnostic tools such as genetic testing or immunologic evaluation [13]. This offers evidence that certain genetic pools may have higher pathogenic mutation levels, urging more epidemiological investigations to investigate these patterns. Understanding local variations in clinical presentation, disease burden, and treatment responses depends on cohort-specific investigations, which, in the end, instruct customized patient care methods.

Age of Onset and Gender Differences

Most APDS cases are identified in the first two decades of life; the condition usually appears in childhood or adolescence [11,13,30]. Bloomfield M et al., 2021, presented eight case reports of patients tracked for APDS and found the median age at diagnosis of APDS to be 16 years (range two to thirty years) [31]. Another research by Tessarin et al., 2020 showed a median age of 12. 9 years and a range of 2. 2 to 43. 2 years [32]. Variability in the age of symptom onset, however, is great; some people may show early signs of the disorder in infancy, but others could go unnoticed until adulthood [31,32]. APDS is often indicated by the early beginning of multiple infections, lymphoproliferation, or autoimmune disorders, therefore urging more study [13]. Both men and women seem to suffer equally from the frequency and harshness of APDS; therefore, gender variations have not been definitively determined. Moreover, the clinical presentations of this disorder may be changed and affected by different genetic, hormonal, or environmental factors, including age of diagnosis and symptom progression in the patients [31,32]. Clinicians must observe these demographic trends to spot at-risk people and apply early treatments.

4. Clinical Features of APDS

Immunological Manifestations

Immune abnormalities ranging from hyperactivation of the PI3Kδ pathway define Activated PI3 Kinase Delta Syndrome (APDS) [13]. These changes mostly influence lymphocyte development, signaling, and activity. Hyperactivation of PI3Kδ in B cells impairs class-switch recombination, therefore decreasing particularly IgG and IgA levels as well as immunoglobulin classes [33]. As a result of this, people frequently have hypogammaglobulinemia or dysgammaglobulinemia, which makes them more vulnerable to infections. In the same way, T-cell function is impaired, with less functional memory T cells being created and weakened cytotoxic activity [12]. Also compromised are regulatory T cells (Tregs), vital for preserving immune tolerance; this further creates immune dysregulation and autoimmunity [34]. Moreover, reduced natural killer (NK) cell activity worsens the immune reaction to viral agents [35]. These immune signs emphasize how difficult APDS is to detect and treat because of its dual nature as an immune dysregulation disorder and a primary immunodeficiency, a uniquely complex condition [13].

Recurrent Infections and Lymphoproliferation

One of the defining characteristics of APDS is repeat infections, which are sometimes serious and hard to control [11]. Often affecting the respiratory system, these are typical viral illnesses [11]. The weakened antibody-mediated immune reaction helps to make encapsulated bacteria, including Streptococcus pneumoniae and Haemophilus influenzae, commonly blamed perpetrators [11]. Also common and sometimes causing long-term and severe sickness are viral infections, especially those induced by herpesviruses, including Epstein-Barr virus (EBV) and cytomegalovirus (CMV) [11]. Repeated respiratory infections sometimes lead to bronchiectasis in patients, therefore increasing long-term morbidity [36]. In addition, skin abscesses are considered common in patients because of staphylococcus aureus infection

[37,38]; however, invasive bacterial infections are considered rare [37], and those infections are mostly observed in humoral deficiencies [39].

Lymphoproliferation, shown as lymphadenopathy, splenomegaly, and hepatomegaly, is another well-known clinical sign of APDS reported in 75% of APDS1 and 89% of APDS2 patients [37,38]. Uncontrolled lymphocyte proliferation from the hyperactive PI3Kδ pathway causes these symptoms [40]. Not only is it a diagnostic indicator, but it also causes significant clinical anxiety, as it may predispose patients to the development of lymphoma, especially non-Hodgkin's lymphoma. [40]. Both subtypes of APDS are at higher risk of developing different types of B cell lymphoma, particularly classical Hodgkin lymphoma, diffuse large B cell lymphoma, and marginal zone B lymphoma [37,41,42].

Autoimmune, Inflammatory Complications and developmental delay

Aside from immunodeficiency, APDS is linked with several different autoimmune and inflammatory issues, showing the dysregulated immune activation produced by PI3Kδ hyperactivity [7]. Common and frequently first seen early in the progression of the disease are autoimmune cytopenias, including autoimmune hemolytic anemia, immune thrombocytopenia (ITP), and autoimmune neutropenia. Also possible are inflammatory disorders similar to systemic autoimmune diseases, including vasculitis or lupus-like syndromes [43].

Gastrointestinal inflammation can look like inflammatory bowel disease (IBD) in APDS sufferers, another serious problem. Not unusual, these signs of chronic diarrhea, stomach discomfort, and malabsorption have a serious impact on the quality of life [44]. Those autoimmune and inflammatory phenomena indicate the complexity of this condition, combining reduced immunity and excessive immune response. Tailoring treatment strategies that frequently combine immunosuppressive drugs, targeted therapies, and supportive care to address the many clinical issues posed by APDS depends on knowledge of these problems.

Additionally, another disorder associated with this condition is neurodevelopmental abnormalities, including speech delay or global developmental delays, which are more commonly reported in patients with APDS2. [10].

5. Diagnosis of APDS

Genetic Testing and Diagnostic Biomarkers

The sure diagnosis of Activated PI3 Kinase Delta Syndrome (APDS) relies on DNA testing to find pathogenic variations in the PIK3CD or PIK3R1 genes [11,12]. In patients with recurrent infections, lymphoproliferation, and immune dysregulation, whole-exome sequencing (WES) or targeted gene panels for primary immunodeficiencies have become indispensable for diagnosing APDS [13]. Besides verifying the diagnosis, genetic testing differentiates between the two subtypes of APDS: APDS1, caused by gain-of-function PIK3CD mutations, and APDS2, caused by PIK3R1 mutations [8]. Early discovery of these mutations is vital as it allows the early start of tailored treatments such as PI3Kδ inhibitors.

Apart from genetic testing, growing diagnostic biomarkers are becoming more relevant. Frequently observed in APDS patients, increased serum IgM levels might provide a starting point in themselves [45,46]. Flow cytometry is another useful tool that exposes distinctive immunologic anomalies, including lower naive T cells, poor memory B cells, and elevated transitionary B cells [47]. Further clues into the functional effects of the mutations might be given by other biomarkers, including hyperphosphorylation of AKT (a downstream target of PI3Kδ) [13]. These diagnostic tools help doctors make accurate diagnoses and understand the molecular and immunological aspects of the condition better.

Differentiation from Other Immunodeficiencies

APDS exhibits clinical and immunological characteristics compared to other primary immunodeficiency disorders, making it a vital part of the diagnosis. Symptoms of conditions, including common variable immunodeficiency (CVID), hyper-IgM syndrome, and other combined immunodeficiencies, usually overlap to include recurrent infections,

lymphoproliferation, and autoimmune problems [48]. Still, some characteristics of APDS can assist in differentiating it from these disorders [13]. For example, lymphadenopathy, splenomegaly, and raised serum IgM levels are more typical of APDS. Moreover, while CVID generally appears later in life, APDS usually starts earlier, sometimes even in childhood or adolescence [11–13].

As it identifies the particular gain-of-function mutations in PIK3CD or PIK3R1 that define APDS, molecular diagnosis via genetic testing is the most dependable way of differentiation [11,12]. Functional experiments, including PI3Kδ overactivation research, can also show abnormal activation of the PI3K-AKT-mTOR pathway [13,48], further justifying the diagnosis. Understanding these differences is key for guaranteeing that patients receive the proper treatment since the therapy for APDS varies quite from that for other immunodeficiencies.

Challenges in Early Diagnosis

Early detection of APDS is still difficult, given its clinical heterogeneity and overlap with other immunological disorders, even if genetic testing technologies have improved [13]. With symptoms sometimes wrongfully imputed to more prevalent illnesses like autoimmune diseases or recurrent infections, many patients suffer a late diagnosis [11]. If left untreated, this diagnostic delay can lead to serious consequences such as permanent organ damage, chronic lung disease, and the development of cancers like lymphoma.

Another difficulty is the variation in the symptom presentation. Though some patients show traditional signs of immunodeficiency, such as frequent respiratory infections, others could have autoimmunity or inflammatory symptoms primarily, therefore complicating the diagnosis [13]. Furthermore, compounding the problem of late diagnosis is the restricted availability of genetic testing and sophisticated immunological evaluations, especially in poor settings [11].

6. Therapeutic Approaches

Evolution of Targeted Therapies

Over the last decade, the Activated PI3 Kinase Delta Syndrome (APDS) treatment scenario has changed considerably from broad immunosuppression and supportive means to molecularly targeted therapies [13,49–51]. Using broad-spectrum antibiotics, immunoglobulin substitution therapy, and corticosteroids, historical treatment for APDS mostly concentrated on managing the symptoms and problems of the illness, including infections, autoimmunity, and lymphoproliferation. Still, these therapies gave only moderate control and did not deal with the fundamental genetic and molecular dysfunction fueling the disease [49].

The discovery of gain-of-function mutations in PIK3CD and PIK3R1 heralded a new age of targeted therapies. These therapies seek to address the underlying cause of APDS by directly suppressing the overactive PI3Kδ pathway, therefore offering more accurate and efficient disease management [24]. Clinical trials of Pi3kδ inhibitors have yielded promising results, demonstrating significant enhancements in immune function, reductions in lymphoproliferation, and stabilization of autoimmune disorders.[24]. The arrival of these treatments changes the way APDS is handled. Hence, patients have hope for improved quality of life and greater disease control.

Role of PI3Kδ Inhibitors (e.g., Leniolisib, Duvelisib)

Due to their capacity to selectively target the hyperactive PI3Kδ pathway, PI3Kδ inhibitors like leniolisib and duvelisib have become fundamental treatments for APDS [52,53]. Leniolisib, a selective PI3Kδ inhibitor, has shown strong activity in APDS patients in reducing lymphoproliferation, boosting the immune system, and relieving autoimmune symptoms. Depending on clinical studies, leniolisib not only reduces spleen size and lymphadenopathy but also enhances important immune regulation markers, including normalization of immunoglobulin levels and recovery of T-cell activity [16,52,54].

Another PI3Kδ inhibitor, duvelisib, has helped to control both autoimmune symptoms and lymphoproliferative features of APDS [52,55]. Originally created for blood cancers, its use in APDS has been investigated since its theory dampens overactive immune signals [52,55]. These inhibitors, like all targeted treatments, have possible adverse effects, including raised infection susceptibility and cytopenias, thus requiring close monitoring throughout therapy [52]. The advent of PI3Kδ inhibitors has transformed APDS treatment, offering specific and potent choices previously not available [55]. These treatments emphasize the need for accurate medicine in tackling uncommon genetic conditions like APDS.

Role of mTOR inhibitor

Sirolimus (Rapamycin) is another medication that works by inhibiting mTOR, which involves T cell metabolism and immune regulation [12]. This medication has been found to be useful in the reduction of hepatosplenomegaly and lymphadenopathy, restoring T cell proliferation, and managing non-neoplastic lymphoproliferation; however, it has a less satisfactory response considering the management of cytopenia and gastrointestinal symptoms [12].

Immune-Modulatory Therapies and Supportive Care

Particularly for treating autoimmune and inflammatory problems, immune-modulatory therapies, besides targeted ones, continue to be a key part of APDS management [8,13]. Corticosteroids are frequently used to manage episodes of acute inflammation, such as vasculitis or autoimmune hemolytic anemia. However, they have significant side effects that restrict their long-term use.[56–58]. Many times, with relatively good clinical results, other immunosuppressive drugs, such as rituximab, have been employed to treat intense lymphoproliferation and unresponsive autoimmune cytopenias [56–58].

Supportive care plays a crucial role in improving the quality of life for individuals with APDS. Immunoglobulin replacement therapy is often used to treat hypogammaglobulinemia and lower repeated infection chances [13]. This supportive care is critical in patients with compromised T-cell or NK cell function, where the application of antibiotics and antifungal medications is critical in avoiding the incidence of serious infections [13]. In addition, vaccination is another approach used to offer protection against particular pathogens. However, its administrated depends on the level of immune dysfunction of the patients. Together, these immune-modulating medications and caring approaches support targeted treatments in providing thorough APDS disease management.

Hematopoietic Stem Cell Transplantation

Hematopotent stem cell transplant (HSCT) provides for those with advanced or obstinate APDS a possible treatment [59]. Replacing the patient's faulty immune system with donor-derived stem cells effectively deals with the underlying genetic and molecular problems [60,61]. Patients with aggressive immune dysregulation, life-threatening lymphoproliferation, or cancer that does not respond to other therapies especially benefit from this method [60].

Although HSCT provides a possibility of cure, it comes with major hazards like graft-versus-host disease (GVHD), infections, and transplant-related death [62,63]. Patients' age, disease severity, and the presence of a good donor all influence the success of HSCT [64]. Though HSCT is still reserved for meticulously selected cases in which the advantages exceed the risks, advances in conditioning regimens and supportive care have improved the outcomes of HSCT for APDS [65].

7. Outcomes and Prognosis

Response of the patients to the treatment and the long-term outcomes

The outcomes for patients diagnosed with APDS have greatly improved after the introduction of those treatments, including PI3Kδ inhibitors. Many treatments result in significant decreases in lymphoproliferation, better management of autoimmune signs, a few recurrent infections, and relieving patients. Leniolisib, for example, has shown continuous efficacy in clinical

studies, including decreases in spleen and lymph node size and increased immune response [66,67]. Rituximab and other treatments like duvelisib and immunomodulators have likewise proven effective in controlling serious lymphoproliferative and autoimmune disorders [8].

Development for people with APDS depends on their age of diagnosis, the extent of signs of the disease, and how soon they receive treatment [11]. Early recognition of a problem and starting therapy are essential in lowering irreversible damage like organ dysfunction or chronic lung damage brought on by continuous inflammation or infections [13]. The current treatment strategies provide the patients with significant relief and control of the condition. However, they do not cure the disease itself [10]. Therefore, in order to ensure the best outcomes for the patient, lifetime monitoring and continual treatment changes according to the progression of the disease are frequently needed.

Risk of Treatment-Associated Complications

Although they are not risk-free, targeted therapies and immune-modulatory medications have transformed the treatment of APDS. For example, by virtue of their immunosuppressive qualities, PI3Kδ inhibitors could raise susceptibility to infections [6,68]. Careful monitoring and prophylactic measures are needed for patients receiving these treatments due to opportunistic infections, including viral or fungal reactivations [6]. Furthermore, in some people, these drugs might be limited by other side effects, including cytopenias, hepatitis, and gastrointestinal issues [68].

The risk of complications is significantly higher in patients undergoing hematopoietic stem cell transplant (HSCT). Common issues include transplant rejection, graft-versus-host disease (GVHD), and the side effects of treatment. Given the extreme immunosuppression needed for the surgery, infections are still a major worry in the post-transplantation phase [69].

Quality of Life and Prognostic Indicators

The chronicity of the illness and its related side effects considerably affects the quality of life of people living with APDS [70]. Patients usually grapple with several issues, such as frequent infections, fatigue, lymphoproliferation, and autoimmune diseases, all of which can have an impact on social, emotional, and physical health. Further aggravating the difficulties faced by these patients are long-term effects, including bronchiectasis, organomegaly, and cancer [13,14]. The constant need for hospital stays, continuous therapies, and possible side effects all too add to a low quality of life.

Notwithstanding these difficulties, a number of elements have been found to predict better results. Early detection and timely introduction of personalized remedies are absolutely vital in reducing damage and retaining organ function [13]. Regular monitoring and supportive treatment, including immunoglobulin replacement therapy, prophylactic antibiotics, and physiotherapy for lung health, also increase quality of life [8]. Therefore, the development of new treatment options and the use of possible gene-editing techniques would be associated with more improvement in this field.

8. Conclusions

The most recent advances in our knowledge of APDS, including its pathophysiology, diagnosis, and treatment, are the main subjects of this review. The primary findings highlight the strong impact of PI3Kδ mutations on the immune dysregulation observed in APDS. Targeted therapies have provided suggestable signs of decreased lymphoproliferation, autoimmune symptom control, and enhancement of immune function, especially PI3Kδ inhibitors like leniolisib and duvelisib. Furthermore, the review highlights the importance of early diagnosis since early detection is essential for identifying patients and customizing drug treatments. Genomic profiling and biomarkers-derived personal medicine offer hope for refining treatment schedules and improving long-term outcomes.

In spite of these advances, the review highlights a number of gaps in the current understanding of APDS. Future research should center on the long-term safety and efficacy of targeted

therapies, alternative genetic variations, and gene-editing technologies, including the possibility of being used as a curative treatment. The review also stresses the constant challenge of managing APDS in light of the need for a multi-disciplinary approach and the complexity of its clinical symptoms. This approach, including immunologists, geneticists, and other specialists, still depends on this to refine outcomes and ensure a comprehensive treatment plan personalized to every patient's individual requirements. As science advances, these findings inspire more effective and tailored future medications.

References:

1. Janku F. Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients. Cancer Treatment Reviews [Internet]. 2017 Jul 19;59:93–101. Available from: https://doi.org/10.1016/j.ctrv.2017.07.005
2. Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, et al. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Molecular Cancer [Internet]. 2023 Aug 18;22(1). Available from: https://doi.org/10.1186/s12943-023-01827-6
3. Okkenhaug K. Signaling by the phosphoinositide 3-Kinase family in immune cells. Annual Review of Immunology [Internet]. 2013 Jan 19;31(1):675–704. Available from: https://doi.org/10.1146/annurev-immunol-032712-095946
4. Piddock R, Bowles K, Rushworth S. The role of PI3K isoforms in regulating bone marrow microenvironment signaling focusing on acute myeloid leukemia and multiple myeloma. Cancers [Internet]. 2017 Mar 28;9(4):29. Available from: https://doi.org/10.3390/cancers9040029
5. Lau A, Avery DT, Jackson K, Lenthall H, Volpi S, Brigden H, et al. Activated PI3Kδ breaches multiple B cell tolerance checkpoints and causes autoantibody production. The Journal of Experimental Medicine [Internet]. 2019 Dec 16;217(2). Available from: https://doi.org/10.1084/jem.20191336
6. Lucas CL, Chandra A, Nejentsev S, Condliffe AM, Okkenhaug K. PI3Kδ and primary immunodeficiencies. Nature Reviews Immunology [Internet]. 2016 Sep 12;16(11):702–14. Available from: https://doi.org/10.1038/nri.2016.93
7. Nunes-Santos CJ, Uzel G, Rosenzweig SD. PI3K pathway defects leading to immunodeficiency and immune dysregulation. Journal of Allergy and Clinical Immunology [Internet]. 2019 May 1;143(5):1676–87. Available from: https://doi.org/10.1016/j.jaci.2019.03.017
8. Serra I, Manusama OR, Kaiser FMP, Floriano II, Wahl L, Van Der Zalm C, et al. Activated PI3Kδ syndrome, an immunodeficiency disorder, leads to sensorimotor deficits recapitulated in a murine model. Brain Behavior & Immunity - Health [Internet]. 2021 Oct 20;18:100377. Available from: https://doi.org/10.1016/j.bbih.2021.100377
9. Narayan N, Hewins P, Lane P, Rhodes B. 47. Activated PI3 kinase delta syndrome: a rare cause of inflammatory disease. Rheumatology Advances in Practice [Internet]. 2018 Sep 1;2(suppl_1). Available from: https://doi.org/10.1093/rap/rky034.010
10. Michalovich D, Nejentsev S. Activated PI3 kinase Delta syndrome: From genetics to therapy. Frontiers in Immunology [Internet]. 2018 Feb 26;9. Available from: https://doi.org/10.3389/fimmu.2018.00369
11. Lougaris V, Piane FL, Cancrini C, Conti F, Tommasini A, Badolato R, et al. Activated phosphoinositde 3-kinase (PI3Kδ) syndrome: an Italian point of view on diagnosis and new advances in treatment. ˜ the œItalian Journal of Pediatrics/Italian Journal of Pediatrics [Internet]. 2024 May 20;50(1). Available from: https://doi.org/10.1186/s13052-024-01662-5

12. Singh A, Joshi V, Jindal AK, Mathew B, Rawat A. An updated review on activated PI3 kinase delta syndrome (APDS). Genes & Diseases [Internet]. 2019 Oct 15;7(1):67–74. Available from: https://doi.org/10.1016/j.gendis.2019.09.015
13. Vanselow S, Wahn V, Schuetz C. Activated PI3Kδ syndrome – reviewing challenges in diagnosis and treatment. Frontiers in Immunology [Internet]. 2023 Jul 20;14. Available from: https://doi.org/10.3389/fimmu.2023.1208567
14. Serra I, Manusama OR, Kaiser FMP, Floriano II, Wahl L, Van Der Zalm C, et al. Activated PI3Kδ syndrome, an immunodeficiency disorder, leads to sensorimotor deficits recapitulated in a murine model. Brain Behavior & Immunity - Health [Internet]. 2021 Oct 20;18:100377. Available from: https://doi.org/10.1016/j.bbih.2021.100377
15. Elworthy S, Rutherford HA, Prajsnar TK, Hamilton NM, Vogt K, Renshaw SA, et al. Activated PI3K delta syndrome 1 mutations cause neutrophilia in zebrafish larvae. Disease Models & Mechanisms [Internet]. 2023 Feb 20;16(3). Available from: https://doi.org/10.1242/dmm.049841
16. Walsh CM, Fruman DA. Too much of a good thing: immunodeficiency due to hyperactive PI3K signaling. Journal of Clinical Investigation [Internet]. 2014 Aug 17;124(9):3688–90. Available from: https://doi.org/10.1172/jci77198
17. Rao VK, Webster S, Dalm V a. SH, Šedivá A, Van Hagen PM, Holland S, et al. Effective "activated PI3Kδ syndrome"–targeted therapy with the PI3Kδ inhibitor leniolisib. Blood [Internet]. 2017 Oct 3;130(21):2307–16. Available from: https://doi.org/10.1182/blood-2017-08-801191
18. Moreno-Corona N, Chentout L, Poggi L, Thouenon R, Masson C, Parisot M, et al. Two monogenetic disorders, activated PI3-Kinase-Δ syndrome 2 and Smith–Magenis syndrome, in one patient: case report and a literature review of neurodevelopmental impact in primary immunodeficiencies associated with disturbed PI3K signaling. Frontiers in Pediatrics [Internet]. 2021 Jun 24;9. Available from: https://doi.org/10.3389/fped.2021.688022
19. Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. Cell [Internet]. 2017 Aug 1;170(4):605–35. Available from: https://doi.org/10.1016/j.cell.2017.07.029
20. Preite S, Cannons JL, Radtke AJ, Vujkovic-Cvijin I, Gomez-Rodriguez J, Volpi S, et al. Hyperactivated PI3Kδ promotes self and commensal reactivity at the expense of optimal humoral immunity. Nature Immunology [Internet]. 2018 Aug 15;19(9):986–1000. Available from: https://doi.org/10.1038/s41590-018-0182-3
21. Stark AK, Davenport ECM, Patton DT, Scudamore CL, Vanhaesebroeck B, Veldhoen M, et al. Loss of phosphatidylinositol 3-Kinase activity in regulatory T cells leads to neuronal inflammation. The Journal of Immunology [Internet]. 2020 May 15;205(1):78–89. Available from: https://doi.org/10.4049/jimmunol.2000043
22. IJspeert H, Dalm V a SH, Van Zelm MC, Edwards ESJ. Hyperactivation of the PI3K Pathway in Inborn Errors of Immunity: current understanding and therapeutic perspectives. Immunotherapy Advances [Internet]. 2024 Jan 1;4(1). Available from: https://doi.org/10.1093/immadv/ltae009
23. Berglund LJ. Modulating the PI3K Signalling Pathway in Activated PI3K Delta Syndrome: a Clinical Perspective. Journal of Clinical Immunology [Internet]. 2023 Dec 27;44(1). Available from: https://doi.org/10.1007/s10875-023-01626-0
24. Smith T, Cunningham-Rundles C. Primary B-cell immunodeficiencies. Human Immunology [Internet]. 2018 Oct 22;80(6):351–62. Available from: https://doi.org/10.1016/j.humimm.2018.10.015

25. Kahan SM, Wherry EJ, Zajac AJ. T cell exhaustion during persistent viral infections. Virology [Internet]. 2015 Jan 22;479–480:180–93. Available from: https://doi.org/10.1016/j.virol.2014.12.033
26. Redenbaugh V, Coulter T. Disorders related to PI3KΔ hyperactivation: Characterizing the clinical and immunological features of activated PI3-Kinase Delta syndromes. Frontiers in Pediatrics [Internet]. 2021 Aug 5;9. Available from: https://doi.org/10.3389/fped.2021.702872
27. Büsch K, Memmott HL, McLaughlin HM, Upton JEM, Harrington A. Genetic Etiologies and Outcomes in Malignancy and mortality in Activated phosphoinositide 3-Kinase Delta Syndrome: a systematic review. Advances in Therapy [Internet]. 2024 Dec 5; Available from: https://doi.org/10.1007/s12325-024-03066-7
28. Bloomfield M, Klocperk A, Zachova R, Milota T, Kanderova V, Sediva A. Natural course of activated phosphoinositide 3-Kinase Delta syndrome in childhood and adolescence. Frontiers in Pediatrics [Internet]. 2021 Jul 19;9. Available from: https://doi.org/10.3389/fped.2021.697706
29. Tessarin G, Rossi S, Baronio M, Gazzurelli L, Colpani M, Benvenuto A, et al. Activated Phosphoinositide 3-Kinase Delta Syndrome 1: Clinical and Immunological Data from an Italian Cohort of Patients. Journal of Clinical Medicine [Internet]. 2020 Oct 17;9(10):3335. Available from: https://doi.org/10.3390/jcm9103335
30. Thouenon R, Moreno-Corona N, Poggi L, Durandy A, Kracker S. Activated PI3Kinase Delta Syndrome—A multifaceted Disease. Frontiers in Pediatrics [Internet]. 2021 Jun 25;9. Available from: https://doi.org/10.3389/fped.2021.652405
31. Honing DY, Luiten RM, Matos TR. Regulatory T cell dysfunction in autoimmune diseases. International Journal of Molecular Sciences [Internet]. 2024 Jun 29;25(13):7171. Available from: https://doi.org/10.3390/ijms25137171
32. Björkström NK, Strunz B, Ljunggren HG. Natural killer cells in antiviral immunity. Nature Reviews Immunology [Internet]. 2021 Jun 11;22(2):112–23. Available from: https://doi.org/10.1038/s41577-021-00558-3
33. Condliffe AM, Chandra A. Respiratory manifestations of the activated phosphoinositide 3-Kinase Delta syndrome. Frontiers in Immunology [Internet]. 2018 Mar 5;9. Available from: https://doi.org/10.3389/fimmu.2018.00338
34. Oh J, Garabedian E, Fuleihan R, Cunningham-Rundles C. Clinical Manifestations and Outcomes of Activated Phosphoinositide 3-Kinase δ Syndrome from the USIDNET Cohort. The Journal of Allergy and Clinical Immunology in Practice [Internet]. 2021 Aug 2;9(11):4095–102. Available from: https://doi.org/10.1016/j.jaip.2021.07.044
35. Nunes-Santos CJ, Uzel G, Rosenzweig SD. PI3K pathway defects leading to immunodeficiency and immune dysregulation. Journal of Allergy and Clinical Immunology [Internet]. 2019 May 1;143(5):1676–87. Available from: https://doi.org/10.1016/j.jaci.2019.03.017
36. Schworer SA, Francis OL, Johnson SM, Smith BD, Gold SH, Smitherman AB, et al. Autoimmune cytopenia as an early and initial presenting manifestation in activated PI3 kinase Delta Syndrome: case report and review. Journal of Pediatric Hematology/Oncology [Internet]. 2021 May 31;43(8):281–7. Available from: https://doi.org/10.1097/mph.0000000000002214
37. Dargenio VN, Rutigliano V, Martire B, Pigneur B, Dargenio C, Francavilla R, et al. Inflammatory bowel disease in activated PI3KΔ syndrome: an uncommon complication of a rare condition. BioMed [Internet]. 2024 Nov 12;4(4):493–8. Available from: https://doi.org/10.3390/biomed4040037
38. Wallace JG, Zambrano-Rodas P, Córdova-Calderón W, Estrada-Turriate S, Mendoza-Quispe D, Ontiveros YL, et al. Dysregulated actin dynamics in activated PI3Kδ syndrome.

Clinical Immunology [Internet]. 2019 Nov 21;210:108311. Available from: https://doi.org/10.1016/j.clim.2019.108311
39. Pham MN, Cunningham-Rundles C. Evaluation of lymphoproliferative disease and increased risk of lymphoma in activated phosphoinositide 3 kinase Delta Syndrome: A case report with discussion. Frontiers in Pediatrics [Internet]. 2018 Dec 18;6. Available from: https://doi.org/10.3389/fped.2018.00402
40. Rawat A, Arora K, Shandilya J, Vignesh P, Suri D, Kaur G, et al. Flow Cytometry for Diagnosis of Primary Immune Deficiencies—A Tertiary Center experience from North India. Frontiers in Immunology [Internet]. 2019 Sep 11;10. Available from: https://doi.org/10.3389/fimmu.2019.02111
41. Gereige JD, Maglione PJ. Current understanding and recent developments in common variable immunodeficiency associated autoimmunity. Frontiers in Immunology [Internet]. 2019 Dec 10;10. Available from: https://doi.org/10.3389/fimmu.2019.02753
42. Coulter TI, Cant AJ. The treatment of activated PI3KΔ syndrome. Frontiers in Immunology [Internet]. 2018 Sep 7;9. Available from: https://doi.org/10.3389/fimmu.2018.02043
43. Rao VK, Pittaluga S, Uzel G. Beyond FAScinating: advances in diagnosis and management of autoimmune lymphoproliferative syndrome and activated PI3 kinase δ syndrome. Hematology [Internet]. 2024 Nov 25;2024(1):126–36. Available from: https://doi.org/10.1182/hematology.2024000537
44. Vanselow S, Hanitsch L, Hauck F, Körholz J, Maccari ME, Meinhardt A, et al. Future Directions in the Diagnosis and Treatment of APDS and IEI: a Survey of German IEI Centers. Frontiers in Immunology [Internet]. 2023 Oct 5;14. Available from: https://doi.org/10.3389/fimmu.2023.1279652
45. Cant AJ, Chandra A, Munro E, Rao VK, Lucas CL. PI3KΔ pathway dysregulation and unique features of its inhibition by leniolisib in activated PI3KΔ syndrome and beyond. The Journal of Allergy and Clinical Immunology in Practice [Internet]. 2023 Sep 28;12(1):69–78. Available from: https://doi.org/10.1016/j.jaip.2023.09.016
46. De SK. Leniolisib: a novel treatment for activated phosphoinositide-3 kinase delta syndrome. Frontiers in Pharmacology [Internet]. 2024 Feb 12;15. Available from: https://doi.org/10.3389/fphar.2024.1337436
47. Rao VK, Šedivá A, Dalm V a SH, Plebani A, Schuetz C, Shcherbina A, et al. A randomised, placebo-controlled, phase III trial of leniolisib in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): Adolescent and adult subgroup analysis. Clinical Immunology [Internet]. 2024 Nov 17;270:110400. Available from: https://doi.org/10.1016/j.clim.2024.110400
48. Randall J, Evans K, Watts B, Smith CM, Hughes K, Earley EJ, et al. In vivo activity of the dual PI3Kδ and PI3Kγ inhibitor duvelisib against pediatric acute lymphoblastic leukemia xenografts. Pediatric Blood & Cancer [Internet]. 2023 May 4;70(8). Available from: https://doi.org/10.1002/pbc.30398
49. Hong Y, Nanthapisal S, Omoyinmi E, Olbrich P, Neth O, Speckmann C, et al. Secondary C1Q deficiency in activated PI3KΔ syndrome type 2. Frontiers in Immunology [Internet]. 2019 Nov 11;10. Available from: https://doi.org/10.3389/fimmu.2019.02589
50. Lu M, Gu W, Sheng Y, Wang J, Xu X. Case report: Activating PIK3CD mutation in patients presenting with granulomatosis with polyangiitis. Frontiers in Immunology [Internet]. 2021 Apr 28;12. Available from: https://doi.org/10.3389/fimmu.2021.670312
51. Sood AK, Francis O, Schworer SA, Johnson SM, Smith BD, Googe PB, et al. ANCA vasculitis expands the spectrum of autoimmune manifestations of activated PI3 kinase δ syndrome. Frontiers in Pediatrics [Internet]. 2023 May 19;11. Available from: https://doi.org/10.3389/fped.2023.1179788

52. Castagnoli R, Delmonte OM, Calzoni E, Notarangelo LD. Hematopoietic stem cell transplantation in Primary Immunodeficiency Diseases: Current status and future Perspectives. Frontiers in Pediatrics [Internet]. 2019 Aug 8;7. Available from: https://doi.org/10.3389/fped.2019.00295
53. Wahlstrom JT, Dvorak CC, Cowan MJ. Hematopoietic stem cell transplantation for severe combined immunodeficiency. Current Pediatrics Reports [Internet]. 2015 Jan 12;3(1):1–10. Available from: https://doi.org/10.1007/s40124-014-0071-7
54. Taylor M, Khan S, Stapleton M, Wang J, Chen J, Wynn R, et al. Hematopoietic stem cell transplantation for mucopolysaccharidoses: past, present, and future. Biology of Blood and Marrow Transplantation [Internet]. 2019 Feb 14;25(7):e226–46. Available from: https://doi.org/10.1016/j.bbmt.2019.02.012
55. Hamouda M, Ebrahim M, Atwa S, Awad D, El-Zayady W, Saleh N. A looming shadow: Impact of parasitic infections in hematopoietic stem cell transplantation: A comprehensive review. Parasitologists United Journal [Internet]. 2024 Aug 1;17(2):74–83. Available from: https://doi.org/10.21608/puj.2024.301795.1255
56. Kurya AU, Aliyu U, Tudu AI, Usman AG, Yusuf M, Gupta S, et al. Graft-versus-host disease: Therapeutic prospects of improving the long-term post-transplant outcomes. Transplantation Reports [Internet]. 2022 Sep 6;7(4):100107. Available from: https://doi.org/10.1016/j.tpr.2022.100107
57. Nademi Z, Slatter MA, Dvorak CC, Neven B, Fischer A, Suarez F, et al. Hematopoietic stem cell transplant in patients with activated PI3K delta syndrome. Journal of Allergy and Clinical Immunology [Internet]. 2016 Nov 12;139(3):1046–9. Available from: https://doi.org/10.1016/j.jaci.2016.09.040
58. Notarangelo LD. Hematopoietic stem cell transplantation for activated phosphoinositide 3-kinase δ syndrome: Who, when, and how? Journal of Allergy and Clinical Immunology [Internet]. 2018 Sep 12;143(1):91–3. Available from: https://doi.org/10.1016/j.jaci.2018.08.039
59. Rao VK, Webster S, Šedivá A, Plebani A, Schuetz C, Shcherbina A, et al. A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome. Blood [Internet]. 2022 Nov 18;141(9):971–83. Available from: https://doi.org/10.1182/blood.2022018546
60. Whalen J, Chandra A, Kracker S, Ehl S, Seidel MG, Gulas I, et al. Comparative efficacy of leniolisib (CDZ173) versus standard of care on rates of respiratory tract infection and serum immunoglobulin M (IgM) levels among individuals with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): An externally-controlled study. Clinical & Experimental Immunology [Internet]. 2024 Dec 2; Available from: https://doi.org/10.1093/cei/uxae107
61. Okkenhaug K, Graupera M, Vanhaesebroeck B. Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis, and immunotherapy. Cancer Discovery [Internet]. 2016 Sep 22;6(10):1090–105. Available from: https://doi.org/10.1158/2159-8290.cd-16-0716
62. Maffini E, Festuccia M, Brunello L, Boccadoro M, Giaccone L, Bruno B. Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation [Internet]. 2016 Dec 27;23(3):388–97. Available from: https://doi.org/10.1016/j.bbmt.2016.12.632
63. Hitchcock I, Skrobanski H, Matter E, Munro E, Whalen J, Nolthenius JT, et al. A qualitative study to explore the burden of disease in activated phosphoinositide 3-kinase delta syndrome (APDS). Orphanet Journal of Rare Diseases [Internet]. 2024 May 18;19(1). Available from: https://doi.org/10.1186/s13023-024-03215-9